GROWTH HORMONE AXIS RESEARCH / DESK NOTES
About This Briefing Desk
A citation-anchored account of the Growth Hormone Axis literature, organized clinician's-briefing style: what it is, what is shown, what to watch, what is unknown.
What this desk covers
Peptide Pros USA is an independent research digest on four Growth Hormone Axis compounds: sermorelin, ipamorelin, CJC-1295, and the CJC-1295/ipamorelin combination. Each is a GHRH analog or growth hormone secretagogue studied for its ability to prompt the pituitary gland's own pulsatile release of growth hormone.
The organizing frame is the sleep-GH connection: the body's largest natural GH pulses cluster around slow-wave sleep, which is both the biological reason these compounds are typically studied and used at bedtime, and the reason better sleep is the most consistently reported effect across every compound page on this site. That consistency is treated here as a pattern worth naming, not as proof — every community report on this site carries an explicit anecdotal label, and every quantitative claim traces to a cited source.
How this desk is built
Each compound page follows the same structure: what the compound is, how it works mechanistically, what controlled research actually measured (with a numbered citation on every quantitative claim), what research-use communities report (labeled anecdotal, never attached to a dose), and what the safety literature flags. A shared references list collects every source cited across all four pages and the comparison.
The four compounds sit at very different points on the evidence spectrum, and this desk does not flatten that difference. Sermorelin carries a genuine FDA approval history. Ipamorelin's only human RCT did not meet its primary endpoint. CJC-1295's human data are a handful of small pharmacology studies. The combination has never been tested as a fixed blend at all — its rationale rests on the two components' separate literature and general receptor cross-talk data. Each page says exactly which of those categories it is in.
The edges of this desk
Peptide Pros USA is not a clinic, a pharmacy, or a vendor. Nothing on this site is sold, sourced, or brokered, and no supplier or clinic pays for placement here. No content on this site names a human dose as a recommendation — where a number appears, it is the dose a specific cited study used, not an instruction. None of the four compounds covered here is approved by the FDA for general adult use; sermorelin's approval was pediatric-specific and has since been withdrawn for commercial reasons, and ipamorelin and CJC-1295 have never been approved for any use.
Anyone considering these compounds for any purpose should take that decision to a licensed clinician. Notes on a stale citation, a new published trial, or a factual correction are welcome through the contact page.